Company: EDSA
Filing Date: 2025-03-11
Form Type: 424B3
Source: 0001171843-25-001403
Chunk: 2

Company: Edesa Biotech, Inc.
Filing Date: 2025-03-11
Form: 424B3
Chunk 2
---
 jurisdiction where
the offer or sale is not permitted.

For investors outside the United States:
neither we nor the Selling Shareholders have done anything that would permit this offering or possession or distribution of this prospectus
in any jurisdiction outside the United States where action for that purpose is required. Persons outside the United States who come into
possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities covered
hereby and the distribution of this prospectus outside the United States.

This prospectus contains summaries of
certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information.
All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have
been filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you
may obtain copies of those documents as described below under “Where You Can Find More Information” and “Incorporation
of Certain Information by Reference.”

We may also provide a prospectus supplement
to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable
prospectus supplement together with the additional information to which we refer you in the sections of this prospectus entitled “Where
You Can Find More Information” and “Incorporation of Certain Information by Reference.”

Unless otherwise stated or the context
otherwise indicates, references to “Edesa,” the “Company,” “we,” “our,” “us,”
or similar terms refer to Edesa Biotech, Inc. and its subsidiaries.

| 1 |

### PROSPECTUS SUMMARY
The following summary highlights some information from this prospectus. It is not complete and does not contain all of the information that you should consider before making an investment decision. You should read this entire prospectus, including the “Risk Factors” section on page 5 of this prospectus and the disclosures to which that section refers you, the financial statements and related notes and the other more detailed information appearing elsewhere or incorporated by reference into this prospectus before investing in any of the securities described in this prospectus.

### Overview
We are a biopharmaceutical
company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize
drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects. We prioritize our